This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.
Inclusion Criteria:
-Patients who receive a Botox® injection for urinary incontinence.
Exclusion Criteria:
-Patients not residing in France.
Giens-Hyeres, 83406, France
Pointoise Cedex, 95301, France
Saint Cyr/Loire, 37540, France